Fundraising Fox
Kiora Pharmaceuticals
NASDAQ: KPRXEncinitas, US · Delaware corporation · 1 known investors
Find your way into Kiora Pharmaceuticals
Sign up to see every warm intro you have to Kiora Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kiora Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company developing small molecule therapies targeting retinal diseases to preserve, slow, or restore vision loss. The company focuses on critical pathways in eye disease for patients seeking advanced ophthalmologic treatments.
Founders & leadership
MT
Melissa ToscaChief Financial OfficerMelissa Tosca is Chief Financial Officer of Kiora Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for retinal diseases. She is a CPA with experience in finance and accounting operations at biotechnology companies, including prior work at a Big Four firm.
SF
Stephen FromExecutive
Board
TB
Thomas BallandBoard director
MC
Mounia ChaouiBoard director
LW
Lisa Walters-HoffertBoard director
DH
David HollanderBoard director
PT
Praveen TyleBoard director
CS
Carmine StengoneBoard director
EP
Erin ParsonsBoard director
AS
Aron ShapiroBoard director
PC
Paul ChaneyBoard director
Investors · 1
VentechreportedParis · $540K – $5.4M
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$51.5M disclosed across 11 of 13 rounds · 2014–2026
▶$5MraisedApr 2026 · 3 investors · PharmaceuticalsRule 506(b)
▶$5MraisedApr 2026 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lisa Walters-HoffertDirector
- David HollanderDirector
- Praveen TyleDirector
- Brian StremExecutive Officer
- Melissa ToscaExecutive Officer
- Carmine StengoneDirector
- Erin ParsonsDirector
- Aron ShapiroDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedFeb 2024 · 13 investors · PharmaceuticalsRule 506(b)
▶$15MraisedFeb 2024 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Praveen TyleDirector
- Brian StremExecutive Officer
- Eric DanielsExecutive Officer
- Carmine StengoneDirector
- Erin ParsonsDirector
- David HollanderDirector
- Melissa ToscaExecutive Officer
- Aron ShapiroDirector
- Kenneth GayronDirector
- Offering amount
- $15M
- Amount sold
- $15M
- Sales commissions
- $1.1M
- Placement agents
- Maxim Group LLC
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedFeb 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedFeb 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brian StremExecutive Officer, Director
- Melissa ToscaExecutive Officer
- Kenneth GayronDirector
- David HollanderDirector
- Paul ChaneyDirector
- Praveen TyleDirector
- Erin ParsonsDirector
- Aron ShapiroDirector
- Eric DanielsExecutive Officer
- Offering amount
- $200K
- Amount sold
- $200K
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MofferedFeb 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$10MofferedFeb 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brian StremExecutive Officer, Director
- David HollanderDirector
- Melissa ToscaExecutive Officer
- Kenneth GayronDirector
- Praveen TyleDirector
- Paul ChaneyDirector
- Eric DanielsExecutive Officer
- Erin ParsonsDirector
- Aron ShapiroDirector
- Offering amount
- $10M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$67.3KraisedNov 2021 · 6 investors · PharmaceuticalsRule 506(b)
▶$67.3KraisedNov 2021 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Aron ShapiroDirector
- Stephen FromExecutive Officer, Director
- Kenneth GayronDirector
- Paul ChaneyDirector
- Brian StremExecutive Officer, Director
- Sarah RomanoExecutive Officer
- Eric DanielsExecutive Officer
- Praveen TyleDirector
- Amount sold
- $67.3K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.8MraisedAug 2021 · 14 investors · PharmaceuticalsRule 506(b)
▶$10.8MraisedAug 2021 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth GayronDirector
- Paul ChaneyDirector
- Sarah RomanoExecutive Officer
- Stephen FromExecutive Officer, Director
- Praveen TyleDirector
- Aron ShapiroDirector
- Brian StremExecutive Officer, Director
- Offering amount
- $10.8M
- Amount sold
- $10.8M
- Sales commissions
- $860K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedJan 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$8MraisedJan 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul ChaneyDirector
- Sarah RomanoExecutive Officer
- Keith MaherDirector
- Thomas HancockDirector
- Praveen TyleDirector
- Morton GoldbergDirector
- Steven BoydDirector
- Bernard Malfroy-CamineDirector
- Stephen FromExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.2MraisedJan 2021 · 15 investors · PharmaceuticalsRule 506(b)
▶$3.2MraisedJan 2021 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Morton GoldbergDirector
- Keith MaherDirector
- Bernard Malfroy-CamineDirector
- Stephen FromExecutive Officer, Director
- Sarah RomanoExecutive Officer
- Paul ChaneyDirector
- Steven BoydDirector
- Praveen TyleDirector
- Thomas HancockDirector
- Amount sold
- $3.2M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$64.4Mvaluation at IPOJul 2015 · $8.50/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 5
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Kira PharmaceuticalsKira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases. Its work combines drug development and protein engineering, supported by academic collaborators and a scientific advisory board in complement biology and immunology.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Coya TherapeuticsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
Companies working in the same space as Kiora Pharmaceuticals.
Frequently asked questions
- What does Kiora Pharmaceuticals do?
- Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company developing small molecule therapies targeting retinal diseases to preserve, slow, or restore vision loss. The company focuses on critical pathways in eye disease for patients seeking advanced ophthalmologic treatments.
- Who are Kiora Pharmaceuticals's investors?
- Kiora Pharmaceuticals's investors include Ventech.
- How much funding has Kiora Pharmaceuticals raised?
- Kiora Pharmaceuticals has disclosed $51.5M raised across 11 of its 13 known rounds.
- Where is Kiora Pharmaceuticals headquartered?
- Kiora Pharmaceuticals is headquartered in Encinitas, US.